Pereţianu D, Deleanu A, Lotreanu V, Mogoş A, Beşliu C, Tănase D
Med Interne. 1985 Jan-Mar;23(1):63-6.
Leukocyte migration inhibitory factor (LMIF) activity was tested before and after glucagon administration both in vivo and in vitro. In vivo glucagon 1 mg i.v. vs saline administration inhibited LMIF production by T lymphocytes in 85.21% patients (p less than 0.01). In vitro glucagon in physiologic (125 pg/ml) and pharmacologic (50 ng/ml) doses increased the migration area vs PPD 250 microL (migration index 0.5127 vs 0.3210; p less than 0.05). These results show a significant inhibitory effect of glucagon upon LMIF activity. We suggest that glucagon acts by enhancement of the intralymphocytic cAMP/cGMP ratio (cyclic adenosine monophosphate/cyclic guanosine monophosphate).
在体内和体外给予胰高血糖素前后均检测了白细胞迁移抑制因子（LMIF）活性。在体内，静脉注射1mg胰高血糖素与注射生理盐水相比，85.21%的患者T淋巴细胞的LMIF产生受到抑制（p<0.01）。在体外，生理剂量（125pg/ml）和药理剂量（50ng/ml）的胰高血糖素与250μL结核菌素纯蛋白衍生物（PPD）相比，增加了迁移面积（迁移指数分别为0.5127和0.3210；p<0.05）。这些结果表明胰高血糖素对LMIF活性有显著的抑制作用。我们认为胰高血糖素通过提高淋巴细胞内的环磷酸腺苷/环磷酸鸟苷（cAMP/cGMP）比值发挥作用。
